IgA Nephropathy Registration Initiative of High Quality (INSIGHT)

ConditionIgA Nephropathy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age14+

SponsorSun Yat-sen University

About this trial

The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure (ESRD, defined as initiation of dialysis or kidney transplantation) of IgAN patients will be compared using the IgAN database.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Biopsy-proven primary IgAN patients;

age ≥14 years old

Adequate biopsy sample containing ≥8 glomeruli.

Disqualifiers

None

Trial population

Biopsy-proven primary IgAN patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

No intervention
Other intervention
Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.

Treatment groups

10,000 Participants

are divided into 1 treatment group

Group A: IgAN patients1 intervention

Trial outcomes

Primary outcomes

All-cause and cardiovascular mortality of IgAN patients

Time frame

10 years

A composite renal outcome of IgAN patients

The composite renal outcome defined as doubling of serum creatinine and ESRD (defined as initiation of dialysis or kidney transplantation).

Time frame

10 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sun Yat-sen University

Lead sponsor

Source ClinicalTrials.gov

Apply now